ArticleVeterinary sciences2026
Development of a Competitive Chemiluminescent Enzyme Immunoassay Based on Recombinant FMDV VP2 Protein for Rapid and Simultaneous Detection of Antibodies Against Foot-and-Mouth Disease Virus Serotypes O and A.
Article in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Timely detection of specific antibodies against foot-and-mouth disease virus (FMDV) is critical to effective prevention and control of the disease. In this study, we developed a competitive chemiluminescent enzyme immunoassay (cCLEIA) based on recombinant FMDV VP2 protein (FMDV-VP2 cCLEIA) for simultaneous detection of antibodies against FMDV serotypes O and A in serum samples. Using a cut-off of 35% percentage inhibition (PI), the FMDV-VP2 cCLEIA achieved a relative sensitivity of 101.5% and a relative specificity of 102% compared with commercial FMDV serotypes O and A liquid-phase blocking ELISA (LPBE) kits. The assay showed high specificity for detection of antibodies against FMDV serotypes A and O, with no cross-reactivity observed against positive sera for classical swine fever virus, porcine reproductive and respiratory syndrome virus, and Senecavirus A. Both intra-batch and inter-batch coefficients of variation were below 15%, confirming excellent assay reproducibility. The testing of 40 field serum samples yielded a positive detection rate of 95% using the FMDV-VP2 cCLEIA, compared with 92.5% using the FMDV serotypes O and A LPBE kits. In conclusion, the FMDV-VP2 cCLEIA developed is a rapid, sensitive assay for simultaneous detection of antibodies against FMDV serotypes O and A, which may offer a valuable tool for foot-and-mouth disease (FMD) surveillance and control programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.